Revvity, Inc. (RVTY)
Company Description
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally.
The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services.
Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.
This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery.
It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name.
The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023.
Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Country | United States |
Founded | 1937 |
Industry | Diagnostics & Research |
Sector | Healthcare |
Employees | 11,500 |
CEO | Dr. Prahlad R. Singh Ph.D. |
Contact Details
Address: 940 Winter Street Waltham, Massachusetts 02451 United States | |
Phone | 781-663-5791 |
Website | perkinelmer.com |
Stock Details
Ticker Symbol | RVTY |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000031791 |
ISIN Number | US7140461093 |
Employer ID | 04-2052042 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Dr. Prahlad R. Singh Ph.D. | Chief Executive Officer, President and Director |
Maxwell Krakowiak | Senior Vice President and Chief Financial Officer |
Tajinder S. Vohra | Senior Vice President of Global Operations |
Joel S. Goldberg | Senior Vice President of Administration, General Counsel and Secretary |
Miriame Victor | Senior Vice President and Chief Commercial Officer |
Andrew Okun | Vice President, Chief Accounting Officer and Treasurer |
Arvind Sundar-Rajan | Vice President of Digital and Technology |
Madhuri Hegde FACMG, Ph.D. | Senior Vice President and Chief Scientific Officer |
Jayashree Thacker | Senior Vice President and Global Chief Information Officer |
Stephen Barr Willoughby | Senior Vice President of Investor Relations and Head of ESG |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 13, 2024 | ARS | Filing |
Mar 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Mar 13, 2024 | DEF 14A | Other definitive proxy statements |
Feb 29, 2024 | 144 | Filing |
Feb 27, 2024 | 144 | Filing |
Feb 27, 2024 | 10-K | Annual Report |
Feb 23, 2024 | 144 | Filing |
Feb 23, 2024 | 144 | Filing |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |